|
|||||
|
|
Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO) |
|
| Authors: | Umut Demirci Gulnihal Tufan Bilge Aktas Ozan Balakan Ahmet Alacacioglu Faysal Dane Huseyin Engin M Ali Kaplan Yusuf Gunaydin Nuriye Y Ozdemir I Tugba Unek Halit Karaca Tulay Akman Ozlem U Sonmez Ugur Coskun Hakan Harputluoglu Alper Sevinc Onder Tonyali Suleyman Buyukberber Mustafa Benekli |
| Institution: | 1. Department of Medical Oncology, Ataturk Training and Research Hospital, Bilkent, Ankara, 0906800, Turkey 2. Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey 3. Department of Medical Oncology, Marmara University Faculty of Medicine, ?stanbul, Turkey 4. Department of Medical Oncology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey 5. Department of Medical Oncology, Katip Celebi University Faculty of Medicine, ?zmir, Turkey 6. Department of Medical Oncology, Zonguldak Bulent Ecevit University Faculty of Medicine, Zonguldak, Turkey 7. Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbak?r, Turkey 8. Department of Medical Oncology, Numune Training and Research Hospital, Ankara, Turkey 9. Department of Medical Oncology, Tepecik Training and Research Hospital, ?zmir, Turkey 10. Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri, Turkey 11. Department of Medical Oncology, Dokuz Eylul University Faculty of Medicine, ?zmir, Turkey 12. Department of Medical Oncology, Sakarya Training and Research Hospital, Sakarya, Turkey 13. Department of Medical Oncology, In?nü University Faculty of Medicine, Malatya, Turkey 14. Department of Medical Oncology, Antakya State Hospital, Antakya, Turkey |
| Abstract: | PurposesThe overall prognosis for recurrent malignant glioma (MG) is extremely poor, and treatment options are limited. We evaluated our multicenter retrospective experience for patients with recurrent MG administering bevacizumab and irinotecan in combination therapy.MethodsA total of 115 patients with grade IV glial tumor (n = 93) and grade III glial tumor (n = 22) were retrospectively evaluated at 14 centers in Turkey. Primary objectives of the study were to evaluate the efficacy and toxicity of the bevacizumab and irinotecan as salvage treatment based on response to therapy, progression-free survival (PFS), 6 months of PFS, overall survival (OS), and 6 months of OS (OS6).ResultsBevacizumab and irinotecan were performed as second line (79.1 %) and third line treatment (20.9 %). Median chemotherapy cycle was 6 (range 1–37), and median follow-up was 6 months (range 1–36 months). Objective response rate was 39.1 %. Six-month PFS and OS6 were 46.3 % and 67.5 %, respectively. Median PFS was 6 months (95 % CI 2.5–9.5) and 6 months (95 % CI 4.9–7.1) in the grade III and IV groups, respectively (p = 0.773). Median OS was 9 months (95 % CI 7.1–10.9) and 8 months (95 % CI 6.6–9.4) in the grade III and IV groups, respectively (p = 0.450). Serious toxicities were observed in 7.8 % of patients. Treatment-related toxic death was observed in 3 patients. There was no treatment related to central nervous system hemorrhage or other serious hemorrhages.ConclusionsPresent study results were consistent with previous studies. In addition, we detected similar outcomes in grade III and IV glial tumors. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |